DMRA

Damora Therapeutics, Inc.

Healthcare · Biotechnology

$87.42 sample

+1.51 (+1.76%) 1D

Market cap

$456.0B

Price as of

2026-10-15

Latest filing

8-K · 2026-10-07

Alerts

8

Price$87.42 +2.09% 3M daily closessample

88.5882.39

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 07SEC10-Q filed
Oct 01INSInsider sell: Chief Financial Officer
Sep 24INSInsider buy: General Counsel
Sep 15INSInsider sell: 10% owner
Sep 07INSInsider sell: Chief Executive Officer
Aug 31SECForm 144 filed
Aug 21SECDEF 14A filed
Aug 17SEC10-Q filed

Sign up to see the real DMRA record →

Company facts

SEC EDGAR registration

Name: Damora Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -20sample, -100 to +100
Reporting currency: USD

Who is positioning in DMRA

sample

Insiders: 20 insider transactions over 90 days, net selling, $241.0M
Congress: 3 members traded over 90 days
Institutions · 13F: 34 funds hold $7.1B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$20.3B +19.5% y/y

Q4 2024Q3 2026

Inventory$11.8B +10.4% y/y

Q4 2024Q3 2026

Accounts receivable$8.8B +10.2% y/y

Q4 2024Q3 2026

Total debt$24.2B +11.0% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $352.0B -4.3% 3M
Sample peer B: $212.9B -11.4% 3M
Sample peer C: $176.0B +8.0% 3M
Sample peer D: $115.1B -4.6% 3M
Sample peer E: $156.1B +16.1% 3M